Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials-Reference-Cited by-同舟云学术

Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials

Published:2017-09 Issue:1-2 Volume:122 Page:113-120
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Elstein Deborah,Mellgard Björn,Dinh Quinn,Lan Lan,Qiu Yongchang,Cozma Claudia,Eichler Sabrina,Böttcher Tobias,Zimran Ari

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference36 articles.

1. Gaucher disease and related lysosomal storage diseases;Zimran,2016

2. Clinical manifestations and management of Gaucher disease;Linari;Clin. Cases Miner. Bone Metab.,2015

3. Biomarkers;Lorne,2013

4. Hyperferritinemia and iron overload in type 1 Gaucher disease;Stein;Am. J. Hematol.,2010

5. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study;Sims;Clin. Genet.,2008

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gaucher disease provides a unique window into Parkinson disease pathogenesis;Nature Reviews Neurology;2024-08-06

2. A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy;Journal of Clinical Medicine;2024-06-05

3. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry;Journal of Clinical Medicine;2024-05-09

4. Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s disease;2024-03-27

5. A Brazilian Rare-Disease Center’s Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF;International Journal of Molecular Sciences;2024-03-01